Objective: The objective of this study is to determine the efficacy of a bolus dose of amiodarone administered by the way of cardiopulmonary bypass pump before releasing of aortic cross-clamp (ACC) in the prevention of atrial fibrillation.Methods: In this prospective study, 22 non-diabetic patients were randomly assigned in a double-blind fashion to either amiodarone or placebo group. In amiodarone group injection amiodarone 3 mg/kg in 10 ml normal saline (amiodarone group, Group A, n=10) and in control group (control group, Group P, n=12), the same volume of normal saline was administered 3 min before the release of ACC. Initial rhythm after the release of ACC was noted.Results: The major rhythm after the release of ACC was ventricular arrhythmia in control group (n=5, 40%), whereas in amiodarone group, it is normal sinus rhythm (n=7, 63%). Only the need of cardioversion/defibrillation and the amount of energy needed was less in the amiodarone group but not reached statistical significance level. There was a trend toward a higher ventricular rate in control group compared to amiodarone group, but it never reached statistical significance level (114±46 vs. 97±29, p=0.3). One patient in amiodarone group required temporary pacemaker for sustained atrioventricular block with heart rate of <50 beats/min and continued on temporary pacemaker for 48 h.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.